Related Experiment Video
Updated: Sep 30, 2025

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography
Published on: February 16, 2016
NOMOGRAM CONTAINING SIMPLE ROUTINE CLINICAL AND BIOCHEMICAL PARAMETERS CAN PREDICT PATHOLOGIC VENTRICULAR REMODELING
Ozren Vinter1, Krešimir Kordić1, Iva Klobučar1
1Sestre milosrdnice University Hospital Centre, Zagreb, Croatia.
Insights
A new nomogram predicts pathologic ventricular remodeling after heart attack using simple blood tests and vital signs. This tool aids early identification of high-risk patients, potentially improving outcomes for myocardial infarction survivors.
Area of Science:
- Cardiology
- Biomedical Engineering
- Clinical Research
Background:
- Heart failure is a major global health concern, often stemming from ischemic heart disease.
- Ventricular remodeling, characterized by increased ventricular volumes, is a key mechanism in heart failure development.
- Early identification of patients at risk for adverse remodeling post-myocardial infarction is crucial.
Purpose of the Study:
- To identify clinical and biochemical predictors of pathologic ventricular remodeling one year after ST-segment elevation myocardial infarction.
- To develop and validate a predictive nomogram for adverse ventricular remodeling.
Main Methods:
- Prospective observational study of 101 patients with ST-segment elevation myocardial infarction.
- Percutaneous coronary intervention within 12 hours and Thrombolysis in Myocardial Infarction III flow achieved.
- Nomogram developed using NTproBNP, aspartate transaminase, systolic blood pressure, and culprit artery; validated with ROC analysis.
Main Results:
- The developed nomogram demonstrated a high predictive value for pathologic ventricular remodeling (Area Under Curve = 0.907).
- Key predictors included NTproBNP and aspartate transaminase levels 12 hours post-reperfusion, admission systolic blood pressure, and culprit coronary artery.
- The nomogram achieved 91.4% sensitivity and 74.0% specificity at a threshold of -3.54.
Conclusions:
- A novel nomogram effectively predicts pathologic left ventricular remodeling after myocardial infarction.
- This low-cost, widely available tool can identify at-risk patients early (12 hours post-reperfusion).
- Further validation is needed, but the nomogram shows promise for guiding early clinical interventions.
Abstract:
Heart failure is the leading cause of morbidity and mortality worldwide, with ischemic heart disease being one of the most important etiologic factors. Heart failure develops due to ventricular remodeling, which leads to increases in left ventricular end-systolic and end-diastolic volumes. In this prospective observational study, we included 101 patients with first episode of ST-segment elevation myocardial infarction in whom percutaneous coronary intervention was conducted within 12 h and Thrombolysis in Myocardial Infarction III flow was achieved. The aim was to determine which clinical and biochemical parameters can help predict pathologic ventricular remodeling 1 year after myocardial infarction. We created a nomogram based on routinely used blood tests and vital parameters which showed highest correlation with pathologic ventricular remodeling. The nomogram included NTproBNP value 12 h after reperfusion, aspartate transaminase value 12 h after reperfusion, systolic blood pressure value on admission, and culprit coronary artery. We performed ROC analysis which yielded great predictive value of the nomogram. The area under curve was 0.907 (95% CI 0.842-0.973). The nomogram value of -3.54 had 91.4% sensitivity and 74.0% specificity. We believe that this nomogram, once validated, could offer a widely available, low-cost option that would help identify patients at risk of developing pathologic left ventricular remodeling and achieve this at a very early stage of myocardial infarction (12 h after reperfusion has been achieved).
Related Concept Videos
Heart Failure IV: Classification and Diagnostic Evaluation
Acute Coronary Syndrome III: Diagnostic Studies
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure II: Pathophysiology

